Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - Lipocine Inc. | v460000_10k.htm |
| EX-32.2 - EXHIBIT 32.2 - Lipocine Inc. | v460000_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - Lipocine Inc. | v460000_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Lipocine Inc. | v460000_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Lipocine Inc. | v460000_ex31-1.htm |
| EX-21.1 - EXHIBIT 21.1 - Lipocine Inc. | v460000_ex21-1.htm |
| EX-10.24 - EXHIBIT 10.24 - Lipocine Inc. | v460000_ex10-24.htm |
| EX-10.23 - EXHIBIT 10.23 - Lipocine Inc. | v460000_ex10-23.htm |
| EX-10.22 - EXHIBIT 10.22 - Lipocine Inc. | v460000_ex10-22.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Lipocine Inc.:
We consent to the incorporation by reference in the Registration Statements (No. 333-199093, No. 333-190897, No. 333-197421, No. 333-191695, and No. 333-214492) on Forms S-3 and S-8 of Lipocine Inc. of our report dated March 6, 2017, with respect to the consolidated balance sheets of Lipocine Inc. as of December 31, 2016 and 2015, and the related consolidated statements of operations and comprehensive loss, stockholders equity, and cash flows for each of the three years in the period ended December 31, 2016, which report appears in the December 31, 2016 annual report on Form 10-K of Lipocine Inc.
/s/ KPMG LLP
Salt Lake City, Utah
March 6, 2017